ArticleInvestigational new drugs2023

Assessment of the potential of the MET inhibitor tepotinib to affect the pharmacokinetics of CYP3A4 and P-gp substrates.

Özkan Yalkinoglu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.